MDGL, US5588681057

Madrigal Pharmaceuticals stock: New F4 study, late-2027 readout

Published on 11/17/2026 at 22:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Madrigal Pharmaceuticals stock gets a fresh conference update. Management outlined a larger F4 study and expects the current trial readout in late 2027.

Madrigal expands its MASH strategy

  • Management presented a larger F4 outcomes study designed to incorporate new biomarker and risk-stratification insights.
  • The ongoing MAESTRO-NASH OUTCOMES trial is now expected to report in late 2027.
  • REZDIFFRA treatment exceeded 55,850 patients, according to the conference discussion.
MDGL, US5588681057, Illustration mit AI erstellt.

Madrigal Pharmaceuticals presented a new, larger F4 outcomes study and narrowed the expected readout for its ongoing MAESTRO-NASH OUTCOMES trial to late 2027 at the Jefferies Global Healthcare Conference on Tuesday, November 17, 2026. A transcript published by Investing.com captured the management discussion.

Madrigal said the new study will use lessons from the current trial, open-label data and newer approaches to identify patients at higher risk of liver-related events. Management described the move as part of a strategy to build a leadership position across F2, F3 and compensated F4 cirrhosis rather than as a response to a weakness in the existing program.

Late-2027 trial timing

The ongoing MAESTRO-NASH OUTCOMES study includes 845 patients with compensated cirrhosis. Chief Medical Officer Dave Berman said the company had accumulated enough events to narrow the expected timing from a broader 2027 window to late 2027, while noting that the final timing depends on the pace of event accumulation.

The planned follow-on study is intended to apply more refined risk stratification, including the ANTICIPATE-NASH algorithm and emerging blood biomarkers. Madrigal said the design will place greater emphasis on patients with features associated with a higher likelihood of progression.

Commercial launch remains central

Management said more than 55,850 patients were receiving REZDIFFRA, the company's treatment for metabolic dysfunction-associated steatohepatitis. It also said quarterly additions were running at roughly 6,000 to 7,000 patients and that real-world safety monitoring had not identified signals inconsistent with the approved label.

Madrigal Pharmaceuticals stock traded at 383.45 euros on Lang & Schwarz at 10:07 p.m. Berlin time on Tuesday, November 17, 2026.

Madrigal Pharmaceuticals

  • Company: Madrigal Pharmaceuticals, Inc.
  • ISIN: US5588681057
  • Ticker: MDGL
  • Home exchange: Nasdaq
  • Lang & Schwarz price: 383.45 euros at 10:07 p.m. Berlin time, November 17, 2026

The Nasdaq Composite provides the relevant market backdrop for Madrigal Pharmaceuticals stock: Current Nasdaq market reports.

More news and analyses on Madrigal Pharmaceuticals stock

Disclaimer...
en | US5588681057 | MDGL | boerse | 70528691 | bgmi